Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD) Horning, S. J., Bartlett, N. L., Breslin, S., Advani, R. H., Hoppe, R. T., Ekstrand, B. C., Lucas, J. B. AMER SOC HEMATOLOGY. 2007: 198A
View details for Web of Science ID 000251100800645